# Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects

> **NCT00197197** · PHASE3 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 18 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** GW873140

## Key facts

- **NCT ID:** NCT00197197
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-07
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** The study was terminated due to hepatoxicity of compound
- **Last updated:** 2011-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00197197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00197197, "Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00197197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*